Kinstellar has advised US-based Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on its acquisition of Praha Vaccines a.s. from the Cyrus Poonawalla Group.
The acquisition includes a vaccine and biologics manufacturing facility and other support buildings in the Czech city of Jevany, together with the company’s employees and all related infrastructure. The value of the transaction was approximately USD 167 million.
According to Kinstellar, "the newly acquired facility is expected to provide an annual production capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373 — Novavax’s COVID-19 vaccine candidate. The acquisition of Praha Vaccines is supported by Novavax’s funding arrangement with the Coalition for Epidemic Preparedness Innovations, which enables Novavax to dramatically expand its manufacturing capacity."
The Kinstellar team was led by Partner Jan Juroska and included Partner Tomas Cihula, Associates Martina Mazurkova and Martin Holub, and Junior Associates Matej Vecera, Stepanka Havlikova, Alice Radvanovska, Veronika Roznovska, and Sabina Skoumalova.
Kinstellar did not reply to our inquiry on the matter.